Ligand Pharmaceuticals (LGND) Convertible Debt (2014 - 2022)

Ligand Pharmaceuticals (LGND) has 9 years of Convertible Debt data on file, last reported at $176.5 million in Q1 2022.

• For the quarter ending Q1 2022, Convertible Debt fell 49.89% year-over-year to $176.5 million; the trailing twelve-month figure through Mar 2022 stood at $176.5 million (down 49.89% YoY), and the FY2021 full-year result was $320.7 million, down 27.49% from the prior year.
• Convertible Debt eased to $176.5 million in Q1 2022, from $320.7 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $639.0 million in Q4 2019 to a low of $16.1 million in Q1 2018.
• A 5-year average of $447.6 million and a median of $449.7 million in 2020 frame the typical range for Convertible Debt.
• Across the five-year window, Convertible Debt jumped 3737.46% in 2019 and tumbled 49.89% in 2022, its largest moves.
• Tracing LGND's Convertible Debt over 5 years: stood at $609.9 million in 2018, then climbed by 4.77% to $639.0 million in 2019, then plunged by 30.78% to $442.3 million in 2020, then dropped by 27.49% to $320.7 million in 2021, then slumped by 44.95% to $176.5 million in 2022.
• Business Quant data shows LGND's Convertible Debt at $176.5 million in Q1 2022, $320.7 million in Q4 2021, and $316.9 million in Q3 2021.